Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Waxman Asks FDA To Explain How Its Regulatory Priorities Aid Public Health

This article was originally published in The Tan Sheet

Executive Summary

House Oversight and Government Reform Committee Chairman Henry Waxman is challenging FDA's priorities, saying the agency appears more interested in loosening marketing restrictions and reducing product liability for drug and device makers than in protecting public health

You may also be interested in...

Chief counsel leaves FDA

Sheldon Bradshaw, chief counsel of FDA, resigned from the agency Sept. 6 to join Hunton & Williams' food and drug law practice, according to the firm. A former Justice Department attorney, Bradshaw served as top lawyer at FDA since 2005, replacing Dan Troy (1"The Tan Sheet" April 11, 2005, p. 7). During his tenure, he reviewed and approved regulations and guidance including a proposed rule clarifying information included in new dietary ingredient notifications and a draft guidance on the kind of scientific data the FDA's Center for Food Safety and Applied Nutrition would find useful in new dietary ingredient submissions. Deputy Chief Counsel Jeffrey Senger will serve as acting chief until a permanent replacement is found, according to FDA staffers in the Office of Chief Counsel...

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.

Track-And-Trace: With Deadline a Year Away, Some Lessons from Early Adopters

EMD Serono has been tracking Serostim packages since 2002; J&J is using Prezista 600 mg as a trial run for serialization.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts